

The logo for DiaSorin, featuring the company name in white serif font on a dark blue rectangular background.

DIASORIN S.P.A.: ON THE STOCK EXCHANGE AT 12.25 EUROS PER SHARE

Saluggia (Vercelli), July 15, 2007 – DiaSorin S.p.A., a company that operates in the global market for in vitro diagnostics developing, producing and marketing reagent kits for laboratory clinical diagnostics, announced the offering price of its shares for the Global Offering, which is being carried out to list the abovementioned shares on the Star segment of the Online Stock Market organized and operated by Borsa Italiana.

The offering price of the shares was set at **12.25 euros per share**, above the low of the announced spread. The value of the minimum lot (300 shares) is 3,675.00 euros, while the value of the minimum expanded lot (3,000 shares) is 36,750.00 euros.

The proceeds from the Global Offering, computed based on the offering price, net of the commissions paid to the Consortium for the Public Offering and the Consortium for the Institutional Placement, which is attributable to the selling shareholders, will amount to 225.5 million euros (249.3 million euros if the greenshoe option is exercised).

Subsequent to the Global Offering, the Company' s capitalization, computed based on the offering price, will be 612.50 million euros (673.75 million euros considering the shares issued upon the implementation of the 2004-2008 Stock Option Plan).

* * *

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group comprises 12 companies based in Europe, the United States, Central and South America. It has about 840 employees, including 70 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and

Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, thyroid pathologies, oncology, fertility testing, etc.

Contacts:

Laura Villa

DiaSorin S.p.A.

Investor Relations Officer

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Pasquo Cicchini

Hill & Knowlton

pcicchini@hillandknowlton.com

+39 02 31914245

+39 335 6417880